Alumis Inc (ALMS NASDAQ) stock market data APIs
$11.1715
-0.2(-1.8%)
as of December 8, 2025
Try our APIs with
free plan!
Alumis Inc Financial Data Overview
Price chart is built with
Anychart
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company's clinical asset comprises ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. It also develops interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.
Prev. Close
11.1715
Open
10.969
High
11.3111
Low
10.57
52 wk Range
2.76-11.4
Market Cap
1 161 M
Shares Outstanding
97 208 K
Revenue
22 121 K
EPS
-1.06
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Alumis Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Alumis Inc data using free add-ons & libraries
Get Alumis Inc Fundamental Data
Alumis Inc Fundamental data includes:
- Net Revenue: 22 121 K
- EBITDA: -439 332 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-13
- EPS/Forecast: -1
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Alumis Inc News
New
Stocks Pressured by Higher Bond Yields
The S&P 500 Index ($SPX) (SPY) today is down -0.15%, the Dow Jones Industrials Index ($DOWI) (DIA) is down -0.10%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.20%. March E-mini S&P future...
Tuesday 11/18 Insider Buying Report: ALMS, LINE
As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys. At A...
NOTV, APLT Lead After-Hours Biotech Gains; ALMS, TELA, CORT, BRTX Also Advance
(RTTNews) - Several small-cap biotech and therapeutics companies posted notable gains in Monday's after-hours trading session, driven by earnings updates, financial guidance, and regulatory developmen...
Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
